ArticleBritish journal of cancer2011
Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.
Article in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).Cancer research and treatment · 2018Trial
- Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Ectopic FGFR1 Increases Intracellular Pool of Cholesterol in Prostate Cancer Cells.International journal of molecular sciences · 2026Article
- Autocrine Fibroblast Growth Factor Receptor 1 Signaling Activates Lactate Dehydrogenase A-Aerobic Glycolysis for Advanced Human Prostate Tumor Growth.Prostate cancer · 2025Article
- AR expression-independent XRCC3 mediates DNA damage-induced p53/Bax signaling pathway activation against prostate cancer.Journal of cancer research and clinical oncology · 2024Article
- Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.The Prostate · 2024Article
- Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance.Frontiers in endocrinology · 2024Review
- VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway.Signal transduction and targeted therapy · 2023Article
- Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.European urology oncology · 2022Article
- Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment.Oncotarget · 2021Article
- Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.PloS one · 2021Article
- Crosstalk between androgen and Wnt/β-catenin leads to changes of wool density in FGF5-knockout sheep.Cell death & disease · 2020Article
- Article
- MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.Prostate cancer and prostatic diseases · 2019Observational
- Growth factors involve in cellular proliferation, differentiation and migration during prostate cancer metastasis.International journal of cell biology and physiology · 2019Article
- Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance.Genome medicine · 2018Article
- Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer.Cold Spring Harbor molecular case studies · 2016Article
- Gene expression profiling analysis of castration-resistant prostate cancer.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- FGFR1 amplification in squamous cell carcinoma of the lung.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2012Article
- Trends in Gene Expression Profiling for Prostate Cancer Risk Assessment: A Systematic Review.Biomedicine hubReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundProstate cancer (PC) represents a global health issue. Treatment for locally advanced and metastatic PC remains unsatisfactory. The androgen receptor (AR) has been validated in having a key role in both naïve and castrate-resistant PC (CRPC). However, the significance of other signalling pathways in CRPC is less well validated.
methodsTo gain a better insight into the molecular signalling cascades involved in clinical CRPC, we performed gene expression profiling using the Illumina DASL assay and studied matched hormone-naive (HN) and CR prostate tumours (n=10 pairs). Ingenuity Pathways Analysis (IPA) was used to identify potential networks involved, and further validation was performed in in vitro cell models and clinical tumours.
resultsExpression of 50 genes was significantly different between HN and CRPC. IPA revealed two networks of particular interest, including AR and FGFR1, respectively. FGFR1 expression was confirmed to be significantly upregulated in CRPC (P ≤ 0.005), and abnormal FGFR1 expression was associated with shorter time to biochemical relapse in HNPC (P=0.006) and less favourable disease-specific survival in CRPC (P=0.018).
conclusionFor the first time, our gene expression profiling experiment on archival tumour materials has identified upregulated FGFR1 expression to be associated with PC progression to the CR state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.